This content is from: Patents
USPTO issues memorandum in response to CellzDirect and Sequenom
The USPTO tells examiners the Federal Circuit’s CellzDirect ruling “highlighted several important points” but says its subject matter eligibility guidance and training examples are already consistent with it
To access our in-house intelligence please request a trial here.
Read this article – and more – for a 30 day period.
REQUEST ACCESSAre you already an Managing IP subscriber? Login here